Summary (tl;dr)

The Trump administration has announced the discontinuation of a Medicare Part D subsidy program after 2026, a move that could lead to increased prescription drug premiums for millions of seniors and disabled Americans starting in 2027.

Essential Background

Medicare Part D offers prescription drug coverage, primarily for self-administered medications, and is available through stand-alone plans or integrated with Medicare Advantage plans. Following the Inflation Reduction Act's (IRA) redesign of Part D, which shifted more costs to plan sponsors, the Centers for Medicare & Medicaid Services (CMS) initiated the Part D Premium Stabilization Demonstration in 2025. This temporary program provided additional federal funds to insurers to help manage and reduce sudden premium increases and wide cost variations for stand-alone Part D plans. This subsidy successfully lowered average monthly premiums for participating stand-alone plans in both 2025 and 2026. Concurrently, the IRA introduced an annual out-of-pocket spending cap of $2,100 for covered Part D prescription drugs, effective in 2026, to enhance affordability and predictability of drug costs. The IRA also expanded eligibility for the Low-Income Subsidy (LIS), also known as "Extra Help," to assist beneficiaries with limited financial resources.

The Full Story

On July 29, 2026, the Trump administration, via CMS, declared its decision to terminate the Part D Premium Stabilization Demonstration at the close of 2026. Consequently, starting in 2027, private insurance companies offering stand-alone Medicare Part D plans will determine their premiums without the federal financial assistance that had been in place since 2025. CMS Administrator Dr. Mehmet Oz stated that the program is no longer necessary, as plan sponsors have gained adequate experience to accurately price their bids for future years. He projected that most beneficiaries would experience premium increases of less than $10, with some potentially seeing lower premiums. However, health policy experts and advocacy groups have expressed concerns that ending this subsidy could result in more substantial premium hikes for a significant portion of the roughly 25 million individuals enrolled in stand-alone Medicare Part D plans. Finalized individual plan premiums for 2027 are expected to be released in September.

Why It Matters

The cessation of the Part D Premium Stabilization Demonstration is a critical development for millions of Medicare beneficiaries, particularly those with stand-alone prescription drug plans, as it may lead to higher monthly premiums beginning in 2027. While the administration reassures the public of market stability and minimal increases, the removal of this subsidy could impose additional financial strain on seniors and disabled individuals living on fixed incomes. This change unfolds amidst other ongoing Medicare Part D reforms from the Inflation Reduction Act, such as the implementation of a $2,100 annual out-of-pocket cap for prescription drug costs and expanded Low-Income Subsidies for 2026. The potential interplay of these varying policy impacts is fueling public interest and searches as beneficiaries seek clarity on their future prescription drug expenses.

Geographic Location

• Washington, D.C., District of Columbia, United States (Centers for Medicare & Medicaid Services announcement)